Safi Shahda

Safi Shahda

Auto-generated profile, based on publicly available information

Safi Shahda

Indiana University, Indianapolis, IN

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2016 in Psychology & Health
Verified
Journal Article
Closed access
CMCatherine E. Mosher
Catherine E. Mosher
RARebecca N. Adams
Rebecca N. Adams
PHPaul R. Helft
Paul R. Helft
BOBert H. O’neil
Bert H. O’neil
SSSafi Shahda
Safi Shahda
VCVictoria L Champion
Victoria L Champion
Objective: This study assessed positive changes in patients with advanced colorectal cancer and their family caregivers following diagnosis. We compared self-reported positive changes within patient-caregiver dyads as well as self-reports and patient reports of positive changes in caregivers. Design: Individual, semi-structured qualitative interviews were conducted with 23 patients with advanced colorectal cancer and 23 caregivers. A theoretical thematic analysis of interview transcripts was framed by posttraumatic growth theory. Results: Patients and caregivers described five positive changes: closer relationships with others, greater appreciation of life, clarifying life priorities, increased faith, and more empathy for others. Additionally, only caregivers reported better health habits following the cancer diagnosis, and a minority of patients and caregivers reported no positive changes. In about half of cases, patients reported at least one positive change that was identical to that of their caregiver. However, in most cases, patient and caregiver reports of the caregiver’s positive change were discrepant. Conclusion: Findings suggest that positive changes are a shared experience for many patient-caregiver dyads and obtaining both patient and caregiver reports of caregiver positive changes provides a more comprehensive understanding of their experience. Interventions may capitalise on positive changes to promote meaningful living in the context of advanced cancer.

26 October 2018 in Cancers
Verified
Journal Article
Open access
PDF file
DGDongsheng Gu
Dongsheng Gu
HLHai Lin
Hai Lin
XZXiaoli Zhang
Xiaoli Zhang
QFQipeng Fan
Qipeng Fan
SCShaoxiong Chen
Shaoxiong Chen
Jingwu XieJingwu Xie
Jingwu Xie
Pancreatic cancer, mostly pancreatic ductal adenocarcinoma (PDAC), is one of the most lethal cancer types, with an estimated 44,330 death in 2018 in the US alone. While targeted therapies and immune checkpoint inhibitors have significantly improved treatment options for patients with lung cancer and renal cell carcinomas, little progress has been made in pancreatic cancer, with a dismal 5-year survival rate currently at ~8%. Upon diagnosis, the majority of pancreatic cancer cases (~80%) are already metastatic. Thus, identifying ways to reduce pancreatic cancer metastasis is an unmet medical need. Furthermore, pancreatic cancer is notorious resistant to chemotherapy. While Kirsten RAt Sarcoma virus oncogene (K-RAS) mutation is the major driver for pancreatic cancer, specific inhibition of RAS signaling has been very challenging, and combination therapy is thought to be promising. In this study, we report that combination of hedgehog (Hh) and Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase (MEK) signaling inhibitors reduces pancreatic cancer metastasis in mouse models. In mouse models of pancreatic cancer metastasis using human pancreatic cancer cells, we found that Hh target gene Gli1 is up-regulated during pancreatic cancer metastasis. Specific inhibition of smoothened signaling significantly altered the gene expression profile of the tumor microenvironment but had no significant effects on cancer metastasis. By combining Hh signaling inhibitor BMS833923 with RAS downstream MEK signaling inhibitor AZD6244, we observed reduced number of metastatic nodules in several mouse models for pancreatic cancer metastasis. These two inhibitors also decreased cell proliferation significantly and reduced CD45+ cells (particularly Ly6G+CD11b+ cells). We demonstrated that depleting Ly6G+ CD11b+ cells is sufficient to reduce cancer cell proliferation and the number of metastatic nodules. In vitro, Ly6G+ CD11b+ cells can stimulate cancer cell proliferation, and this effect is sensitive to MEK and Hh inhibition. Our studies may help design novel therapeutic strategies to mitigate pancreatic cancer metastasis.

1 June 2016 in The Oncologist
Verified
Journal Article
Open access
PDF file
SSSafi Shahda
Safi Shahda
PLPatrick J. Loehrer
Patrick J. Loehrer
RCRomnee S. Clark
Romnee S. Clark
ASA. John Spittler
A. John Spittler
SASandra K. Althouse
Sandra K. Althouse
ECE. Gabriella Chiorean
E. Gabriella Chiorean
Lessons Learned: Combination therapies in patients with hepatocellular carcinoma can be associated with overlapping toxicity and are therefore poorly tolerated. Using sorafenib at the maximum tolerated dose can lead to a higher incidence of toxicities. Consequently, combination studies might evaluate sorafenib at alternative schedules or doses to improve tolerance, recognizing this could affect sorafenib efficacy. Although this combination was poorly tolerated, it does not exclude further evaluation of new-generation immunomodulator drugs or immune checkpoint inhibitors in the hope of optimizing tolerance and safety.Background.: Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC), and to date, no combination therapy has demonstrated superior survival compared with sorafenib alone. The immunosuppressive microenvironment in HCC is a negative predictor for survival. Lenalidomide is an immunomodulator and antiangiogenic agent, with limited single-agent efficacy in HCC. Based on these data, we designed a phase I study of sorafenib plus lenalidomide to determine the safety and preliminary antitumor activity of this combination.Methods.: This was an open-label, phase I study with a 3+3 dose escalation/de-escalation design. The starting dose of sorafenib was 400 mg p.o. b.i.d. and of lenalidomide was 15 mg p.o. daily with a planned dose escalation by 5 mg per cohort up to 25 mg daily. Dose de-escalation was planned to a sorafenib dose of 400 mg p.o. daily combined with two doses of lenalidomide: 10 mg p.o. daily for a 28-day cycle (cohort 1) and 10 mg p.o. daily for a 21- or 28-day cycle (cohort 2). Patients with cirrhosis, a Child-Pugh score of A-B7, and no previous systemic therapy were eligible.Results.: Five patients were enrolled. Their median age was 56 years (range 39–61), and the ECOG status was 0–2. Four patients were treated at dose level (DL) 1. Because of the poor tolerance to the combination associated with grade 2 toxicities, one more patient was treated at DL −1. No dose-limiting toxicity was observed as specified per protocol. The most common toxicities were nausea, anorexia, pruritus, elevated liver enzymes, and elevated bilirubin. Three patients experienced one or more of the following grade 3 toxicities: fatigue (DL 1), increased bilirubin (DL 1), skin desquamation (DL −1), and elevated transaminase levels (DL 1). The median duration of therapy was 1 cycle (range 1–3). All patients discontinued the study, 4 because of progressive disease and 1 by patient preference. The best confirmed response was progressive disease. The median progression-free survival was 1.0 month (95% confidence interval 0.9–2.8), and the median overall survival was 5.9 months (95% confidence interval 3.68–23.4).Conclusion.: In our small study, the combination of lenalidomide and sorafenib was poorly tolerated and showed no clinical activity. Although the study was closed early because of toxicity concerns, future studies assessing combinations of sorafenib with new-generation immunomodulator drugs or other immunomodulatory agents, should consider lower starting doses of sorafenib to avoid excessive toxicity.

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
BEBassel F. El-Rayes
Bassel F. El-Rayes
SSSafi Shahda
Safi Shahda
ASAlexander Starodub
Alexander Starodub
BOBert H. O'Neil
Bert H. O'Neil
WHWahid Tewfik Hanna
Wahid Tewfik Hanna
TBTanios S. Bekaii-Saab
Tanios S. Bekaii-Saab
4128 Background: BB608 (aka napabucasin, BBI-608) is an oral first-in-class cancer stemness inhibitor that works by targeting Stat3-driven gene transcription. Preclinical anti-tumor activity was observed in vitro and in vivo. BB608 has shown clinical safety and encouraging signs of anti-cancer activity in multiple cancer types in phase I/II studies. Methods: A phase Ib extension, open label, multi-center study in pts with metastatic pancreatic ductal adenocarcinoma (mPDAC) was undertaken to confirm the RP2D, PK profile and signs of anticancer activity of BB608 in combination with gemcitabine and nab-PTX. BB608 was administered at 240 mg BID in combination with gemcitabine 1000 mg/m2 and nab-PTX 125 mg/m2 administered weekly for 3 out every 4 weeks until progression of disease, unacceptable toxicity, or other discontinuation criterion. Results: Of 37 pts enrolled, 31 (84%) were treatment-naïve and 6 (16%) received neoadjuvant systemic therapy. There were no dose-limiting or unexpected toxicities. Most common adverse events (AE’s) related to BB608 included grade 1 diarrhea, abdominal pain, nausea, and fatigue with grade 3 adverse events observed in 6 pts: 1 pt (diarrhea), 1 pt (dehydration), 3 pts (fatigue, hypokalemia) and 1 pt (hyponatremia). No significant pharmacokinetic interactions were observed. Disease control (PR+SD) was observed in 27 of 29 evaluable pts (93%), with 23 pts (79.3%) with tumor regression of which 10 pts (34.5%) achieved PR (RECIST 1.1: 33 - 78% regression). Of the 8 pts who were non-evaluable for treatment response, 3 stopped treatment due to clinical progression, 1 due to non-compliance, and 4 withdrew consent. Among 37 pts enrolled (intent-to-treat), disease control (PR+SD) was observed in 27 pts (73%), with tumor regression observed in 23 pts (62.2%) of which 10 pts achieved PR (27%). Conclusions: This phase Ib extension study confirmed that BB608 can be combined with gemcitabine and nab-PTX and shows encouraging signs of anti-tumor activity in pts with pancreatic cancer. Clinical trial information: NCT02231723.

1 February 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SSSafi Shahda
Safi Shahda
BEBassel F. El-Rayes
Bassel F. El-Rayes
BOBert H. O'Neil
Bert H. O'Neil
ASAlexander Starodub
Alexander Starodub
WHWahid Tewfik Hanna
Wahid Tewfik Hanna
TBTanios S. Bekaii-Saab
Tanios S. Bekaii-Saab
284 Background: BBI-608 is an oral first-in-class cancer stemness inhibitor that works by blocking STAT3-mediated transcription of cancer stemness genes. Potent anti-CSC activity was observed in vitro and in vivo, in mono- and combination therapy. In phase I studies, BBI-608 was generally well tolerated with encouraging signs of anti-tumor activity. Methods: A phase Ib open label, multi-center study in pts with mPDAC was performed to determine RP2D, safety, tolerability, and preliminary anti-cancer activity of BBI-608 in combination with Gemcitabine and nab-PTX. BBI-608 was administered at 240 mg BID in combination with Gemcitabine 125 mg/m2 and nab-PTX 1000 mg/m2administered weekly for 3 out every 4 weeks until progression of disease, unacceptable toxicity, or other discontinuation criterion was met. Results: 31 pts were enrolled and received BBI-608 in combination with Gemcitabine and nab-PTX for a total sum of 83 study cycles. 25 of 31 pts (80.6%) were treatment-naïve and 6 pts (19.4%) received 1 prior line of systemic therapy. Most common adverse events included grade 1 diarrhea, abdominal pain, nausea, and fatigue. Combination treatment was well tolerated with no dose-limiting toxicity observed and safety profile similar to that of each agent individually. One patient experienced grade 3 event of dehydration related to protocol therapy which resolved with hydration. Of the 8 pts enrolled in the RP2D determination portion of the study, 7 pts were evaluable for response with disease control (PR + SD) was observed in 7/7 pts (100%). Tumor regression was observed in 6/7 (85.7%) with 3 PR (41.3%, 37.6% and 33.3% regression) and 3 SD (25.8%, 21.1%, and 19.9% regression). The median progression free survival was 7.8 months with PR or SD of > 6 months in 6/8 pts (75%). Conclusions: This phase Ib study demonstrated that BBI-608 at 240 mg BID can be safely combined with Gemcitabine and nab-PTX. Encouraging anti-tumor activity with durable response was observed in pts with mPDAC. Clinical trial information: NCT02231723.

1 June 2018 in Clinical Colorectal Cancer
Verified
Journal Article
Open access
SASamantha Armstrong
Samantha Armstrong
HAHayma Al-Ghawi
Hayma Al-Ghawi
PHPaul Helft
Paul Helft
MHMichael G. House
Michael G. House
ASAaron J. Spittler
Aaron J. Spittler
SSSafi Shahda
Safi Shahda